We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

15 hedge funds and large institutions have $10.4M invested in Barinthus Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

15% more capital invested

Capital invested by funds: $9.02M → $10.4M (+$1.33M)

7% more funds holding

Funds holding: 14 → 15 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.55% less ownership

Funds ownership: 23.08% → 22.53% (-0.55%)

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$37.5K
2
HF
HRT Financial
New York
+$25.2K
3
XT
XTX Topco
Cayman Islands
+$16.3K
4
Morgan Stanley
Morgan Stanley
New York
+$113
5
UBS Group
UBS Group
Switzerland
+$16

Top Sellers

Rank Fund Capital Flow
1
Baird Financial Group
Baird Financial Group
Wisconsin
-$106K
2
GS
Gilead Sciences
California
-$92.5K
3
Citadel Advisors
Citadel Advisors
Florida
-$14.8K
4
NECFA
New England Capital Financial Advisors
Connecticut
-$42
Name Holding Trade Value Shares
Change 		Change in
Stake
MGP
1
M&G plc
United Kingdom
$5.2M – – –
HH
2
HSG Holding
Hong Kong
$1.96M – – –
AI
3
Alphabet Inc
California
$1.89M – – –
DF
4
DC Funds
Virginia
$803K – – –
JHU
5
Johns Hopkins University
Maryland
$153K – – –
Baird Financial Group
6
Baird Financial Group
Wisconsin
$134K -$106K -85,000 -44%
Renaissance Technologies
7
Renaissance Technologies
New York
$82.9K +$37.5K +30,000 +83%
HighTower Advisors
8
HighTower Advisors
Illinois
$46.8K – – –
HF
9
HRT Financial
New York
$25K +$25.2K +20,152 New
Janney Montgomery Scott
10
Janney Montgomery Scott
Pennsylvania
$19K – – –
XT
11
XTX Topco
Cayman Islands
$16.3K +$16.3K +13,007 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$14.5K – – –
Morgan Stanley
13
Morgan Stanley
New York
$6.18K +$113 +90 +2%
UBS Group
14
UBS Group
Switzerland
$16 +$16 +13 New
SS
15
SBI Securities
Japan
$1 +$1 +1 New
GS
16
Gilead Sciences
California
– -$92.5K -99,478 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$14.8K -16,227 Closed
NECFA
18
New England Capital Financial Advisors
Connecticut
– -$42 -45 Closed

BRNS Hedge Fund Activity: Q3 2025 in Review

15 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2025, worth a combined $10.4M — up 15% from $9.02M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BRNS positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $37.5K. The largest seller was Baird Financial Group, cutting an estimated $106K.

  • 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2025, up from 14 in Q2 2025.
  • Funds reported $10.4M of Barinthus Biotherapeutics stock for Q3 2025, up 15% quarter-over-quarter.
  • 4 funds opened new Barinthus Biotherapeutics positions in Q3 2025 and 3 closed out, a net change of +1 holder.
  • The largest Barinthus Biotherapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $37.5K added.
  • The largest Barinthus Biotherapeutics seller in Q3 2025 was Baird Financial Group, an estimated $106K sold.

Based on aggregated 13F filings for Q3 2025.